ClinicalTrials.gg
CompletedNCT04357795Updated Feb 6, 2024Results posted

Effect of Cequa™ in Subjects With Dry Eye Disease

A Phase 4 interventional study of CequaTM (Cyclosporine 0.09%) ophthalmic solution in Dry Eye Disease, sponsored by Sun Pharmaceutical Industries Limited. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-06.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Enrollment
7th of 41
135 · median 51
Started
2020
with 6 others
Phase 4
23 of 45
3 open now
Registered
25th of 45
by date
Lead sponsor
2 of 45
Sun Pharmaceutical Industries Limited

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 7th largest by enrollment of the 41 interventional ones that give a count, is one of 7 that started in 2020, is one of 23 in phase 4, and was the 25th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.

Read the detailed description

This is a phase 4, multicenter, open-label, single-arm, 12-week study of subjects with dry eye disease that is inadequately controlled by cyclosporine (CsA) 0.05% ophthalmic emulsion. Subject enrollment will be classified by evidence of dry eye disease (ie, signs, symptoms, or both signs and symptoms). Treatment will be one drop of CsA 0.09% ophthalmic solution (Cequa) in each eye twice daily (BID) for 12 weeks. The study hypothesis is that CsA 0.09% ophthalmic solution will show improved clinical benefit in subjects whose dry eye signs and/or symptoms are inadequately controlled while on CsA.

03

Conditions studied

  • Dry Eye Disease

Keywords

  • Keratoconjunctivitis Sicca
  • KCS
  • Dry eye
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects with a history of bilateral dry eye disease for a period of at least 3 months.
  2. Aged of at least 18 years.
  3. Subjects with total corneal fluorescein staining ≥6 or corneal fluorescein staining in an individual zone ≥2 as per National Eye Institute Grading Scale.
  4. Subjects with modified symptom assessment in dry eye global symptom score, ≥40 using visual analogue scale.
  5. Subjects with best-corrected visual acuity 20/200 or better in both eyes at the Screening/Baseline visit

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have used cyclosporin 0.05% ophthalmic emulsion in both eyes for less than 3 months prior to the Screening/Baseline visit.
  2. Subjects with history of treatment failure with cyclosporin 0.05% ophthalmic emulsion.
  3. Subjects who have active seasonal and/or perennial allergic conjunctivitis in either eye.
  4. Subjects who had already Use initiated any systemic or topical ocular medication.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    CequaTM (Cyclosporine 0.09%) ophthalmic solution

    Drug: CequaTM (Cyclosporine 0.09%) ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Baseline in Total Corneal Fluoroscein Staining Score

    Scale for Corneal Staining as defined by the FDA/NEI: 0-4 (0-no staining, 4-severe staining). The higher number indicates more severe. The lower the number indicates less severe staining on the cornea

    Time frame: Week12

  2. Change From Baseline in Modified Dry Eye Scoring.

    Based on questionnaire asked to subjects (sign and symptoms), modified symptom of dry eye score (range 0 to 100) will be assessed. Increase in score will indicate severity in the symptoms.

    Time frame: Week12

Secondary outcomes

  1. Mean Change in Baseline for Conjunctival Staining Assessment

    Based on Investigator's judgement, 6 areas of the conjunctiva will be evaluated in a low to moderate intensity. Scale for Conjunctival Staining defined: 0-6 (0 no staining, 6-severe staining). The higher the number indicates more severe. The lower the number indicates less severe staining on the conjunctival

    Time frame: Week 12

  2. Changes From Baseline in Central Corneal Staining Score

    Five areas of cornea will be evaluated on a 0 to 4 scale and value from 0 (absent) to 4 (severe) to each section will be allotted based on NEI grading scale

    Time frame: Week 12

  3. Mean Change in Baseline for Tear Osmolarity Score for Both Eyes

    Tear osmolarity of both the eyes will be assessed and score (mOsm/L) will be allotted to each eye. Higher score will indicate severity of the disease (dry eye). Tear osmolarity OU was assessed using the TearLab Osmolarity System Test by collecting nanoliter volumes of tear fluid at each visit from each eyelid margin using the Osmolarity Test Pen and Test Card. Results were interpreted according to the provided instructions and scores (mOsm/L) for each eye were recorded. Normal, mild/moderate, and severe dry eyes had average tear osmolarity values of approximately 302+/-8 mOsm/L, 315+/-10 mOsm/L and 336+/022 mOsm/L, respectively.

    Time frame: Week 12

  4. Mean Change From Baseline in Frequency of Artificial Tear Product Use.

    Based on entries in the subject diaries, frequency of artificial tear product use will be assessed. Frequency for artificial tear: This is number of times per day recorded in a daily diary log assessed at baseline and week 12. The higher the number the worse the outcome. The lower the number the better the outcome

    Time frame: Week 12

  5. Schirmer's Test Score

    An unanesthetized Schirmer's test was performed in each eye at least 5 minutes after the lissamine green conjunctival staining to allow for any reflex tearing to subside. At each visit, strips were placed OU at the same time and timed for 5 min. Strips were removed after 5 min and the amount of wetting was recorded in mm and also marked with a line on the strip. The Investigator recorded a score for each eye. A score of greater than 10 mm in 5 minutes is accepted as normal. A score of less than 5 mm in 5 minutes indicates a tear deficiency. A score less than 10 mm in 5 minutes indicates a change from normal in tear production.

    Time frame: Week 12

  6. Percentage of Subjects Who Prefer Study Treatments Over Prior Treatment.

    Subjects will be asked, which treatment they prefer for the management of the dry eye (prior treatment or study treatment). Note- For this outcome measure, participants were provided the option to not choose either treatment as the preferred treatment.

    Time frame: Week 12

07

Results

Posted Feb 6, 2024

Participant flow

Participant flow — Overall Study
MilestoneCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Started134
Completed115
Not completed19

Outcome measures

PrimaryMean Change in Baseline in Total Corneal Fluoroscein Staining Score

Scale for Corneal Staining as defined by the FDA/NEI: 0-4 (0-no staining, 4-severe staining). The higher number indicates more severe. The lower the number indicates less severe staining on the cornea

Time frame:
Week12
Reported as:
Mean · score on a scale
Mean Change in Baseline in Total Corneal Fluoroscein Staining Score
score on a scaleCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Mean Change in Baseline in Total Corneal Fluoroscein Staining Score-3.1 ± 2.88
Statistical analysis
  • CequaTM (Cyclosporine 0.09%) Ophthalmic Solution · Paired t-test · p = <0.0001
PrimaryChange From Baseline in Modified Dry Eye Scoring.

Based on questionnaire asked to subjects (sign and symptoms), modified symptom of dry eye score (range 0 to 100) will be assessed. Increase in score will indicate severity in the symptoms.

Time frame:
Week12
Reported as:
Mean · score on a scale
Change From Baseline in Modified Dry Eye Scoring.
score on a scaleCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Change From Baseline in Modified Dry Eye Scoring.-29.14 ± 26.220
Statistical analysis
  • CequaTM (Cyclosporine 0.09%) Ophthalmic Solution · Paired t-test · p = <0.0001
SecondaryMean Change in Baseline for Conjunctival Staining Assessment

Based on Investigator's judgement, 6 areas of the conjunctiva will be evaluated in a low to moderate intensity. Scale for Conjunctival Staining defined: 0-6 (0 no staining, 6-severe staining). The higher the number indicates more severe. The lower the number indicates less severe staining on the conjunctival

Time frame:
Week 12
Reported as:
Mean · score on a scale
Mean Change in Baseline for Conjunctival Staining Assessment
score on a scaleCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Mean Change in Baseline for Conjunctival Staining Assessment-2.35 ± 2.918
Statistical analysis
  • CequaTM (Cyclosporine 0.09%) Ophthalmic Solution · Paired t-test · p = <0.0001
SecondaryChanges From Baseline in Central Corneal Staining Score

Five areas of cornea will be evaluated on a 0 to 4 scale and value from 0 (absent) to 4 (severe) to each section will be allotted based on NEI grading scale

Time frame:
Week 12
Reported as:
Mean · score on a scale
Changes From Baseline in Central Corneal Staining Score
score on a scaleCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Changes From Baseline in Central Corneal Staining Score-0.5 ± 0.87
Statistical analysis
  • CequaTM (Cyclosporine 0.09%) Ophthalmic Solution · Paired t-test · p = <0.0001
SecondaryMean Change in Baseline for Tear Osmolarity Score for Both Eyes

Tear osmolarity of both the eyes will be assessed and score (mOsm/L) will be allotted to each eye. Higher score will indicate severity of the disease (dry eye). Tear osmolarity OU was assessed using the TearLab Osmolarity System Test by collecting nanoliter volumes of tear fluid at each visit from each eyelid margin using the Osmolarity Test Pen and Test Card. Results were interpreted according to the provided instructions and scores (mOsm/L) for each eye were recorded. Normal, mild/moderate, and severe dry eyes had average tear osmolarity values of approximately 302+/-8 mOsm/L, 315+/-10 mOsm/L and 336+/022 mOsm/L, respectively.

Time frame:
Week 12
Reported as:
Mean · mOsm/L
Mean Change in Baseline for Tear Osmolarity Score for Both Eyes
mOsm/LCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
OD- Right eye-4.0 ± 19.44
OS- left eye-11.7 ± 18.54
Statistical analysis
  • CequaTM (Cyclosporine 0.09%) Ophthalmic Solution · Paired t-test · p = 0.0323OD- Right eye p value
  • CequaTM (Cyclosporine 0.09%) Ophthalmic Solution · Paired t-test · p = 0.3447 (OS: P-Value)
SecondaryMean Change From Baseline in Frequency of Artificial Tear Product Use.

Based on entries in the subject diaries, frequency of artificial tear product use will be assessed. Frequency for artificial tear: This is number of times per day recorded in a daily diary log assessed at baseline and week 12. The higher the number the worse the outcome. The lower the number the better the outcome

Time frame:
Week 12
Reported as:
Mean · times product used/day
Mean Change From Baseline in Frequency of Artificial Tear Product Use.
times product used/dayCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Mean Change From Baseline in Frequency of Artificial Tear Product Use.-1.5 ± 2.39
Statistical analysis
  • CequaTM (Cyclosporine 0.09%) Ophthalmic Solution · Paired t-test · p = <0.0001
SecondarySchirmer's Test Score

An unanesthetized Schirmer's test was performed in each eye at least 5 minutes after the lissamine green conjunctival staining to allow for any reflex tearing to subside. At each visit, strips were placed OU at the same time and timed for 5 min. Strips were removed after 5 min and the amount of wetting was recorded in mm and also marked with a line on the strip. The Investigator recorded a score for each eye. A score of greater than 10 mm in 5 minutes is accepted as normal. A score of less than 5 mm in 5 minutes indicates a tear deficiency. A score less than 10 mm in 5 minutes indicates a change from normal in tear production.

Time frame:
Week 12
Reported as:
Mean · mm
Schirmer's Test Score
mmCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Schirmer's Test Score2.4 ± 8.61
Statistical analysis
  • CequaTM (Cyclosporine 0.09%) Ophthalmic Solution · Paired t-test · p = 0.0029
SecondaryPercentage of Subjects Who Prefer Study Treatments Over Prior Treatment.

Subjects will be asked, which treatment they prefer for the management of the dry eye (prior treatment or study treatment). Note- For this outcome measure, participants were provided the option to not choose either treatment as the preferred treatment.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Subjects Who Prefer Study Treatments Over Prior Treatment.
percentage of participantsCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Prefer prior treatment21.8
Prefer study treatment69.4

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CequaTM (Cyclosporine 0.09%) Ophthalmic Solution0/134 (0%)0/134 (0%)20/134 (14.9%)
Most frequent other events
Most frequent other events
EventCequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Instillation Site IrritationGeneral disorders17/134
Instillation Site PainGeneral disorders3/134

Baseline characteristics

Age, Continuous
Age, Continuous(years)CequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Mean65.5 (23 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)CequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Female110
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CequaTM (Cyclosporine 0.09%) Ophthalmic Solution
Hispanic or Latino18
Not Hispanic or Latino107
Unknown or Not Reported0
08

Study locations

5 sites
  • Eye Associates of Fort Myers, 4225 Evans Ave.
    Fort Myers, Florida 33901, United States
  • Bowden Eye and Associates, 7205 Bonneval Road
    Jacksonville, Florida 32256, United States
  • Eye Center of N Florida, 2500 Martin Luther King Jr Blvd
    Panama City, Florida 32405, United States
  • Kannarr Eye Care, 2521 N Broadway
    Pittsburg, Kansas 66762, United States
  • Texas Eye and Laser Center, 1872 Norwood Dr. #200
    Hurst, Texas 76054, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jun 2022, 23 months.

Results were first posted in Feb 2024, 1 year 7 months after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 23 months is above that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2020
First posted
Apr 22, 2020
StartActual
Jun 29, 2020
Primary completionActual
Jun 24, 2022
CompletionActual
Jun 24, 2022
Results first posted
Feb 6, 2024
Last update
Feb 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04357795
Responsible party
Sponsor
First posted
Apr 22, 2020
Start date
Jun 29, 2020
Primary completion
Jun 24, 2022
Completion
Jun 24, 2022
Results posted
Feb 6, 2024
Last update
Feb 6, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion